Stock Scan December 2017: Teva Stick, Valeant Carrot Spur Generics Revival
The end-of-year stock valuations across Big Pharma jumped nearly 3% in December led by financial reassurances at Valeant and gleeful shareholder reaction to ceremonial employee sacrifices at Teva.
You may also be interested in...
Label restriction, discussions with regulators should keep vaccine in use, Sanofi suggests; Philippines suspended its vaccination program after data showed product can worsen disease in those not previously exposed to infection.
After seven months of uncertainty, Teva has announced a new CEO. But Kåre Schultz, who has won applause for turning around the fortunes of Danish firm Lundbeck over the past two years, faces a daunting turnaround challenge when it comes to the generics behemoth.
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.